Inhalation

INH1026

Issue link: https://www.e-digitaleditions.com/i/1546950

Contents of this Issue

Navigation

Page 30 of 43

Inhalation OctOber 2026 29 from our group shows that liposomes have a limited loading capacity and using a high initial loading titer can cause more phages to remain unencapsulated, outside the liposomes [36]. erefore, there is a need for optimization of phage encapsulation in liposomes. Li, et al. studied the influence of lipid composition on phage protection during nebulization using a vibrating mesh nebulizer (Aeroneb ® Go, Aerogen) [39]. Phage-liposome nanocomplexes were formu- lated with individual lipid egg phosphatidylcholine (EPC), soybean phosphatidylcholine (SPC) or hydro- genated soybean phosphatidylcholine (HSPC) in combination with cholesterol, at a molar ratio of 3:1. Overall, all phage-liposome nanocomplexes resulted in lower phage loss (less than 1.3 log) compared to free phage suspensions (2.0 log). e viability loss upon nebulization across the various liposome nano- complexes was lipid-dependent. Lipids EPC and SPC, which had a lower phase transition tempera- ture (less than -15 °C), showed lower viability loss (6-fold and 13-fold, respectively) compared to lipid HSPC, which had a higher phase transition tempera- ture (52 °C) and showed greater viability loss with an 18-fold reduction. e lower phase transition temperature enables formation of stable droplets, while lipids like HSPC are relatively more rigid. In comparison, in our study using HSPC-Cholesterol- DSPE-PEG liposomes, the phage viability loss was only 10-fold with a jet nebulizer (Pari LC Plus ® , Pari Pharma GmbH). Another study by Cao, et al. exam- ined the effect of using a cationic lipid (DOTAP) in combination with DSPC, Tween 80 and cholesterol to encapsulate phages (PEV2 and PEV40) [40]. It was observed that the phage liposomes exhibited minimal viability loss (0.07 log) using both a jet neb- ulizer (Pari LC ® Sprint) and a vibrating mesh nebu- lizer. e respirable fraction was higher in the case of the vibrating mesh nebulizer (70%) compared to the jet nebulizer (44%) [40]. All these findings point to the importance of understanding the influence of lipid composition, lipid type, phage type and phage- device compatibility in designing phage- encapsulated liposomes for inhalation. Apart from their protective effect during phage neb- ulization, liposomes can help overcome physiological barriers to phage action. Liposomes have been used for their intracellular delivery capabilities. Internal- ization of phage liposomes has shown promise in targeting intracellular bacteria such as M. tuberculo- sis and S. aureus. As described earlier, phage cellular uptake at off-target sites or in the presence of extra- cellular bacteria may reduce phage availability [41]. Our recent publication demonstrated that PEGylated phage liposomes reduced phage cellular uptake by lung epithelial cells. is strategy can help prolong retention of phages outside the lung epithelial cells for targeting extracellular bacteria like P. aeruginosa. Rhein, Germany). e highest phage titer loss was observed with the jet nebulizer (3.7 log), whereas the vibrating mesh nebulizer and the soft mist inhaler led to lower loss (0.4 - 0.5 log) [27]. e fine particle fraction (FPF) i.e., phage dose corresponding to par- ticles less than 5 mm, was also tested. A larger FPF was observed with the soft-mist inhaler (69%), com- pared to the jet nebulizer or vibrating mesh nebulizer (both exhibiting 56% FPF). In another study, com- paring nebulization of P. aeruginosa phages (PELP20 and PELI40), the jet nebulizer outperformed the mesh nebulizer in terms of fine particle fraction and reduced titer loss [28]. ese conflicting findings suggest that the effect of nebulization on phage via- bility may vary on a case-by-case basis, depending on the nebulizer type and phage morphology or the excipients used in the phage suspension. Many studies have reported loss of structural integrity such as broken phage tails, ruptured capsids or leak- age of genetic material upon nebulization, observed using transmission electron microscopy (TEM) [25, 29-31]. Mechanical stresses during nebulization can- not be prevented. erefore, it is critical to investigate these effects and potential protection mechanisms to maintain phage viability. It is also important to assess the phage-device compatibility to achieve minimum viability loss and maximum phage deposition. Phage encapsulation in nanoparticles e encapsulation of phages in nanoparticles (lipo- somes or polymeric nanoparticles) offers a protective strategy that can limit exposure to external stresses. Limited studies are available on the application of phage encapsulation for inhalation, with liposomes gaining more attention compared to polymeric nanoparticles. Liposomes are lipid-based systems consisting of a lipid bilayer with an enclosed aque- ous core. Pulmonary delivery of drugs using lipo- somes can help achieve controlled or sustained drug release, intracellular delivery and precision targeting [32-34]. Liposomal amikacin (Arikayce ® , Insmed, Inc., Bridgewater, New Jersey, US) is a commercial product, approved by the FDA for the treatment of Mycobacterium avium complex (MAC) lung disease [35]. Phage encapsulation in liposomes is more com- monly studied for oral therapy. e encapsulation of phages in liposomes can be achieved using thin-film hydration or microfluidics methods [36, 37]. Studies suggest that microfluidics encapsulates phages with a lower loss in phage viabil- ity (less than 0.25 log loss) [38] compared to thin-film hydration (0.5 log loss and greater) [36]. is indicates that microfluidics is a gentler process than thin-film hydration, which involves extrusion. During extru- sion, phages are exposed to high shear stress that can result in relatively higher phage viability loss. Apart from the process, lipid composition, loading capacity, phage type and loading phage titer can influence the encapsulation of phages in liposomes. A recent study

Articles in this issue

view archives of Inhalation - INH1026